This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?
by Zacks Equity Research
VEEV leans on Vault R&D for growth as AI-native rivals rise, testing its edge in clinical and regulatory innovation.
Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
by Ahan Chakraborty
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
by Ahan Chakraborty
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
by Ahan Chakraborty
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
by Ahan Chakraborty
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation
by Harshit Gupta
Veeva's new AI layer in Vault boosts automation and deepens pharma reliance, sharpening its edge in life sciences tech.
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
by Ahan Chakraborty
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of -15.49% and 6.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Standard BioTools (LAB) delivered earnings and revenue surprises of 0% and 1.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 121.05% and 2.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?
by Zacks Equity Research
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of -57.14% and 5.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 23.26% and 4.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last?
by Zacks Equity Research
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of -30% and 13.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
The Joint Corp. (JYNT) Q3 Earnings Match Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of 0% and 5.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 36.59% and 1.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Schrodinger (SDGR) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of 12.94% and 17.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of 0% and 11.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?